Purine Nucleoside Synthesis via Stereoselective Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for synthesizing purine phosphoramidates, particularly 2′-deoxy-2′-fluoro-2′-C-methyl purine nucleosides, face challenges such as low yields, complex stereoselectivity, and high costs due to difficulties in forming the 2′ quaternary center and obtaining reactive α-halosugars, which hinder their use as effective inhibitors for Hepatitis C virus (HCV).
Innovation Solution
A process involving stereoselective reduction of a protected ribonolactone to a beta-lactol derivative and subsequent stereoselective conversion to an anomeric alpha-derivative, using hydride reducing agents and specific reagents, to produce compounds with improved beta-lactol and anomeric alpha configurations, enhancing the synthesis of purine nucleosides like compound I or II with specific substituents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional methods are used to synthesize purine phosphoramidates, then the synthesis can be completed, but the yields are poor and stereoselectivity is poor
Solution Approach 1:
The patent applies preliminary action by pre-forming the 2'-deoxy-2'-fluoro-2'-C-methyl ribose sugar component with the correct stereochemistry before the coupling step. The sugar is synthesized with the 2'-fluoro and 2'-C-methyl groups already in place with proper configuration, eliminating the need for difficult stereoselective control during the ribose-purine coupling step and achieving both high yield and excellent stereoselectivity.
Solution Approach 2:
The patent segments the synthesis into two independent parts: synthesis of the 2'-deoxy-2'-fluoro-2'-C-methyl ribose sugar component and synthesis of the purine phosphoramidate component, followed by coupling. This segmentation allows each component to be optimized independently, with the sugar component being pre-formed with correct stereochemistry, thereby resolving the contradiction between yield and stereoselectivity.
2Manufacturing precision
If α-halosugar is used to achieve desired β isomer enrichment, then stereoselectivity improves, but it is difficult to obtain the desired reactive α-halosugar in good yield without difficult purification steps
Solution Approach 1:
The patent avoids the need to obtain reactive α-halosugar by pre-forming the 2'-deoxy-2'-fluoro-2'-C-methyl ribose sugar with the correct stereochemistry through a different route. The sugar is synthesized with the 2'-fluoro and 2'-C-methyl groups already in place, eliminating the need for subsequent stereoselective transformation steps that would require difficult-to-obtain α-halosugars.
3Manufacturing precision
If enzymatic glycosylation is used to achieve highly stereospecific coupling, then stereoselectivity improves, but the cost of synthesis increases due to need for specialized enzymes or genetic engineering
Solution Approach 1:
The patent employs conventional chemical reagents and methods instead of expensive specialized enzymes or genetically engineered enzymes. The synthesis uses standard organic chemistry transformations with readily available materials, achieving the desired stereoselectivity through carefully designed chemical steps rather than relying on costly enzymatic catalysts.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the efficient synthesis of purine nucleosides with enhanced stereoselectivity and yield, potentially leading to more effective therapeutic agents against HCV by overcoming previous synthesis hurdles and cost issues.
Implementation Method 1
stereoselective reduction of a protected ribonolactone to a beta-lactol derivative
Implementation Method 2
subsequent stereoselective conversion to an anomeric alpha-derivative
Data Source
AI summary
A process for preparing phosphoramidate prodrugs or cyclic phosphate prodrugs of nucleoside derivatives, which is a compound, its stereoisomers, salts (acid or basic addition salts), hydrates, solvates, or crystalline forms thereof.